Literature DB >> 17953925

[Agreement between REGICOR and SCORE scales in identifying high cardiovascular risk in the Spanish population].

Vicente Gil-Guillén1, Domingo Orozco-Beltrán, Antonio Maiques-Galán, José Aznar-Vicente, Jorge Navarro, Luis Cea-Calvo, Fernando Quirce-Andrés, Josep Redón, Jaime Merino-Sánchez.   

Abstract

INTRODUCTION: The aims of this study were to evaluate the consistency between the SCORE (Systematic Coronary Risk Evaluation) and REGICOR (Registre Gironí del cor) scales in identifying high cardiovascular risk and to describe the characteristics of those individuals for whom scale results were discrepant.
METHODS: This cross-sectional study involved 8942 subjects aged 40-65 years who had an indication for a complete lipid profile. The agreement between SCORE (for low-risk countries) and Framingham-REGICOR (with a high risk threshold of 10%) scales in classifying patients as high risk was evaluated using the kappa statistic. Subjects for whom there was a discrepancy between classifications were identified and variables associated with this discrepancy were determined by multivariate analysis involving binary logistic regression.
RESULTS: The REGICOR scale classified 6.7% of subjects (95% confidence interval [CI], 6.2%-7.3%) as high-risk, while SCORE classified 12.5% (95% CI 11.8%-13.2%) as high-risk. Discrepant findings were observed in 10.2% of the total population (8% had a high risk on SCORE but not REGICOR, and 2.2% had a high risk on REGICOR but not SCORE; kappa=0.420; P< .001). The best agreement was observed between SCORE and REGICOR with a high-risk threshold of 8% (kappa=0.463). Multivariate analysis showed that a high risk on SCORE but not REGICOR was associated with lower age, female sex, a high fasting glucose level, and raised diastolic blood pressure, and a high risk on REGICOR but not SCORE, with male sex, smoking, and a low high-density lipoprotein (HDL) cholesterol level. These variables accounted for the extent of the discrepancy in 93.2% of cases.
CONCLUSIONS: The SCORE and REGICOR (threshold 10%) scales identified different populations as being at a high risk, though the agreement between them was reasonably good. The concurrence of a number of factors (e.g., male sex, low HDL-cholesterol, and smoking) in a subject with a low risk on the SCORE scale should be regarded as increasing the cardiovascular risk.

Entities:  

Mesh:

Year:  2007        PMID: 17953925     DOI: 10.1157/13111236

Source DB:  PubMed          Journal:  Rev Esp Cardiol        ISSN: 0300-8932            Impact factor:   4.753


  4 in total

1.  Agreement between the SCORE and D'Agostino Scales for the classification of high cardiovascular risk in sedentary spanish patients.

Authors:  Manuel A Gómez-Marcos; Gonzalo Grandes; José A Iglesias-Valiente; Alvaro Sánchez; Imanol Montoya; Luis García-Ortiz
Journal:  Int J Environ Res Public Health       Date:  2009-11-11       Impact factor: 3.390

2.  Therapeutic implications of selecting the SCORE (European) versus the D'AGOSTINO (American) risk charts for cardiovascular risk assessment in hypertensive patients.

Authors:  Manuel A Gómez-Marcos; Carlos Martínez-Salgado; Carlos Martin-Cantera; José I Recio-Rodríguez; Yolanda Castaño-Sánchez; Maria Giné-Garriga; Emiliano Rodriguez-Sanchez; Luis García-Ortiz
Journal:  BMC Cardiovasc Disord       Date:  2009-05-11       Impact factor: 2.298

3.  SCORE and REGICOR function charts underestimate the cardiovascular risk in Spanish patients with rheumatoid arthritis.

Authors:  Carmen Gómez-Vaquero; Alfonso Corrales; Andrea Zacarías; Javier Rueda-Gotor; Ricardo Blanco; Carlos González-Juanatey; Javier Llorca; Miguel A González-Gay
Journal:  Arthritis Res Ther       Date:  2013-08-21       Impact factor: 5.156

4.  Prediction of Cardiovascular Disease by the Framingham-REGICOR Equation in the High-Risk PREDIMED Cohort: Impact of the Mediterranean Diet Across Different Risk Strata.

Authors:  Antonio J Amor; Mercè Serra-Mir; Miguel A Martínez-González; Dolores Corella; Jordi Salas-Salvadó; Montserrat Fitó; Ramón Estruch; Lluis Serra-Majem; Fernando Arós; Nancy Babio; Emilio Ros; Emilio Ortega
Journal:  J Am Heart Assoc       Date:  2017-03-13       Impact factor: 5.501

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.